SBIR/STTR Research Award

Nanowire Optical Assay Probe

Award identifier 4ab8945e0c046ce930edb9dc92f03ff704455a16315d995fbdd3e810618541f8Awarding agency Department of Energy

Award amount

$99,999

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Energy
Branch
Not reported
Recipient company
Illuminex Corporation
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
DE-FG02-06ER06-09
Topic code
04

Research abstract

78999S The development of new technologies for the rapid and accurate detection of indicators of diseases such as cancer will have a significant impact on human health. Current diagnostics are performed in highly sophisticated clinical laboratories, which requires significant overhead investment in instrumentation and highly trained medical technology staff. Furthermore, most tests are time consuming and the waiting period causes significant anxiety in patients. This project will develop a real-time, nanowire optical assay probing system for the detection of disease indicators. The technology will be portable, accurate, cost effective, and easy to use. It will simplify medical diagnostics in the doctor¿s office, making results available immediately, and provide a means of testing where clinical laboratory work is not an option (e.g., first responders or medical workers in third world countries). Phase I will demonstrate that a novel probe comprised of bio-chemically functionalized nanowire arrays can be utilized for highly sensitive detection of disease indicators using optical analysis techniques. To show proof-of-principle, the probe will be used to detect a protein indicative of ovarian cancer, CA 125. In Phase II, the range of analytes will be expanded and the nanowire probe will be integrated with the optical and electronic sub-assemblies required to develop a commercially viable, hand-held, highly sensitive, fully functional medical diagnostic instrument. Commercial Applications and Other Benefits as described by the awardee: The current commercial market for in vitro medical diagnostics is $38 billion/year. The technology would replace hundreds of assays in the clinical and research laboratory with a hand-held, instrument that provides an instant readout of results. The versatility of this technology would make it applicable to the detection of a broad range of human health indicators including: infectious diseases, autoimmune diseases, tumor markers, thyroid function, fertility markers, allergy and humoral immunity, cardiac markers, hormone levels, therapeutic drug monitoring, and toxicology/drugs of abuse. Further, the technology could be adapted for the early and accurate detection of chemical and biological weapons and for environmental monitoring of pollution in water or air and contaminants in food.

Technology keywords

Not reported

Agency intelligence

Department of Energy

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.